| Literature DB >> 30775695 |
Sibanarayan Rath1, Saumya Ranjan Das2, Rabindra Nath Padhy1.
Abstract
OBJECTIVE: Identification of otomycotic fungi using matrix-assisted laser desorption ionization (MALDI) time of flight (TOF) mass spectroscopy (MS) and to quantify pervasive errors with Bayes rule; values of sensitivity and specificity of culture test and MALDI-TOF-MS method are quantified.Entities:
Keywords: Identification at species level; MALDI-TOF-MS system; Otomycosis; Sensitivity; Specificity
Year: 2019 PMID: 30775695 PMCID: PMC6364575 DOI: 10.1016/j.wjorl.2018.03.006
Source DB: PubMed Journal: World J Otorhinolaryngol Head Neck Surg ISSN: 2095-8811
Fig. 1Identification of A. niger (A) and C. albicans (B), in SDA plate isolates from ear-swab samples of otomycosis as well as A. niger (C) and C. albicans (D) in a microscope.
Fig. 2A mass spectrometric peptide/protein profiles of A. niger (A) and C. albicans (B), as graphical windows evaluated by the software Biospean. Blue peaks are detected ions and red peaks are the matching peak-positions between both spectra.
The generic 2 × 2 table with number of cases based on MALDI-TOF-MS test and culture test Results during diagnosis with sensitivity and specificity rates of both tests of otomycosis.
| Culture test | MALDI-TOF-MS test | Total | Sensitivity (true positive rate) | Specificity (true negative rate) | |
|---|---|---|---|---|---|
| Positive | Negative | ||||
| Positive | TP = 14 (0.33) | FP = 04 (0.095) | (TP + FP) = 18 (0.43) | TP/(TP + FN) | TN/(FP + TN) |
| Negative | FN = 02 (0.095) | TN = 22 (0.48) | (FN + TN) = 24 (0.57) | 0.875 | 0.846 |
| Total | (TP + FN) = 16 (0.38) | (FP + TN) = 26 (0.62) | N = 42 (1.0) | ||
TP = 14 cases were true-positives (MALDI-TOF-MS test-positive, culture test-positive); FP = 04 cases were false-positives (culture test-positive, MALDI-TOF-MS test-negative); FN = 02 cases were false-negatives (MALDI-TOF-MS test-positive, culture test-negative); and TN = 22 samples were true-negatives (MALDI-TOF-MS test-negative, culture test-negative); N = population size or total number of cases. Corresponding fraction values are given in parentheses. FP cases are the type I errors, while FN cases are the type II errors.
Fig. 3A. niger in (A) and C. albicans in (B), In vitro susceptibilities of clinical isolates fungus to six antifungal agents: A: Amphotericin B; B: Itraconazole; C: Voriconazole; D: Posaconazole; E: Caspofungin; F: Griseoflavin.
In vitro susceptibilities of clinical fungal isolates to six antifungal agents. MIC ranges, geometric mean, as well as values of MIC50 and MIC90 are expressed in μg/ml.
| Isolated fungus | Antifungal agent | MIC (μg/ml) | ||
|---|---|---|---|---|
| MIC range | MIC50 | MIC90 | ||
| Amphotericin B | 0.25–8 | 0.5 | 1 | |
| Itraconazole | 0.031–2 | 0.25 | 0.5 | |
| Voriconazole | 0.031–4 | 0.5 | 0.5 | |
| Posaconazole | 0.008–0.5 | 0.25 | 0.25 | |
| Caspofungin | 0.008–0.25 | 0.15 | 0.063 | |
| Griseoflavin | 0.008–0.5 | 0.016 | 0.063 | |
| Amphotericin B | 0.25–8 | 0.5 | 1 | |
| Itraconazole | 0.031–2 | 0.25 | 0.5 | |
| Voriconazole | 0.031–4 | 0.5 | 0.5 | |
| Posaconazole | 0.008–0.5 | 0.25 | 0.25 | |
| Caspofungin | 0.008–0.25 | 0.15 | 0.063 | |
| Griseoflavin | 0.008–0.5 | 0.016 | 0.063 | |
| Amphotericin B | 0.25–8 | 0.5 | 1 | |
| Itraconazole | 0.031–2 | 0.25 | 0.5 | |
| Voriconazole | 0.031–2 | 0.5 | 0.5 | |
| Posaconazole | 0.008–0.5 | 0.25 | 0.25 | |
| Caspofungin | 0.008–0.25 | 0.15 | 0.063 | |
| Griseoflavin | 0.008–0.5 | 0.016 | 0.063 | |
| Amphotericin B | 0.25–4 | 0.5 | 1 | |
| Itraconazole | 0.031–1 | 0.25 | 0.5 | |
| Voriconazole | 0.031–4 | 0.5 | 0.5 | |
| Posaconazole | 0.008–0.25 | 0.25 | 0.25 | |
| Caspofungin | 0.008–0.25 | 0.15 | 0.063 | |
| Griseoflavin | 0.008–0.5 | 0.016 | 0.063 | |
| Amphotericin B | 0.25–8 | 0.5 | 1 | |
| Itraconazole | 0.031–1 | 0.25 | 0.5 | |
| Voriconazole | 0.031–2 | 0.5 | 0.5 | |
| Posaconazole | 0.008–0.25 | 0.25 | 0.25 | |
| Caspofungin | 0.008–0.25 | 0.15 | 0.063 | |
| Griseoflavin | 0.008–0.5 | 0.016 | 0.063 | |
| Amphotericin B | 0.25–8 | 0.5 | 1 | |
| Itraconazole | 0.031–2 | 0.25 | 0.5 | |
| Voriconazole | 0.031–4 | 0.5 | 0.5 | |
| Posaconazole | 0.008–0.25 | 0.25 | 0.25 | |
| Caspofungin | 0.008–0.25 | 0.15 | 0.063 | |
| Griseoflavin | 0.008–0.5 | 0.016 | 0.063 | |
| Amphotericin B | 0.25–8 | 0.5 | 1 | |
| Itraconazole | 0.031–1 | 0.25 | 0.5 | |
| Voriconazole | 0.031–4 | 0.5 | 0.5 | |
| Posaconazole | 0.008–0.25 | 0.25 | 0.25 | |
| Caspofungin | 0.008–0.25 | 0.15 | 0.063 | |
| Griseoflavin | 0.008–0.5 | 0.016 | 0.063 | |
| Amphotericin B | 0.25–8 | 0.5 | 1 | |
| Itraconazole | 0.031–4 | 0.25 | 0.5 | |
| Voriconazole | 0.031–4 | 0.5 | 0.5 | |
| Posaconazole | 0.008–0.25 | 0.25 | 0.25 | |
| Caspofungin | 0.008–0.25 | 0.15 | 0.063 | |
| Griseoflavin | 0.008–0.5 | 0.016 | 0.063 | |
| Amphotericin B | 0.25–4 | 0.5 | 1 | |
| Itraconazole | 0.031–1 | 0.25 | 0.5 | |
| Voriconazole | 0.031–4 | 0.5 | 0.5 | |
| Posaconazole | 0.008–0.25 | 0.25 | 0.25 | |
| Caspofungin | 0.008–0.25 | 0.15 | 0.063 | |
| Griseoflavin | 0.008–0.5 | 0.016 | 0.063 | |
MIC: Minimum inhibitory concentration.